Anteris Technologies US

A new class (biomimetic) of TAVR valve designed to mimic the performance of a healthy aortic valve for patients suffering from aortic stenosis .

The page highlights the DurAVR THV’s biomimetic design, which mimics a healthy aortic valve’s performance, and presents the latest clinical data.

The randomized head-to-head trial is evaluating the DurAVR THV System compared to commercially available Transcatheter Aortic Valve Replacement (TAVR) devices in patients with severe aortic stenosis.

The page presents data on aortic flow dynamics and the potential benefits of restoring physiologic laminar flow for LV mass regression and cardiac recovery after TAVR.

The New York Valves symposium explores why some patients experience symptoms despite favorable post-TAVR pressure gradients, focusing on physiologic flow patterns and valve performance.

In these short educational videos, Drs. Christopher Meduri and João Cavalcante discuss the flow dynamics and the potential upstream and downstream consequences of different flow patterns resulting from aortic stenosis and aortic valve replacement

Anteris Technologies CEO Wayne Paterson connected live from Tbilisi, Georgia, to discuss the DurAVR THV First-in-Human study with implanting physicians Dr. Christopher Meduri and Dr. Vinayak Bapat.

This webinar discusses how DurAVR THV restores laminar flow, improving LV function and mass regression in AS patients, shifting focus from traditional metrics to whole-heart function.

The page provides access to Anteris Technologies’ press releases, corporate news, and company updates.

New York Valves presented DurAVR THV First-in-Human study data, highlighting laminar flow restoration and its potential downstream benefits, as discussed by imaging expert Dr. João Cavalcante.

Drs. Nicolas Van Mieghem, Christopher Meduri, and Azeem Latib discuss the DurAVR transcatheter heart valve’s biomimetic design and its effects on hemodynamics and blood flow.

View the latest updates from Anteris Technologies, including the latest events, presentations, interviews, and ASX AVR investor company news.

The executive board consists of Wayne Paterson, David St Denis, Brent Moen, and Eric Schwartz.

Brent Moen has been Anteris' Chief Financial Officer since September 2026

Chris Meduri has served as Anteris's Chief Medical Officer since August 2021.

David St Denis was appointed President and Director in March 2025 and is also the Chief Executive Officer of v2vmedtech, inc.

The page outlines Anteris Technologies Global Corp.’s corporate governance framework, policies, and practices, including governance documentation and guidelines.

Anteris Technologies is a structural heart company focused on disrupting heart valve disease and restoring healthy heart function by pioneering science-driven and measurable advancements.

Anteris Technologies is a structural heart company delivering a first-of-its-kind biomimetic TAVI designed to mimic the performance of a healthy aortic valve

The policy describes how Anteris Technologies Global Corp. collects, uses, holds, and discloses personal information.